Navigation Links
Newer Sedative May Reduce Delirium in ICU Patients
Date:2/2/2009

Dexmedetomidine might become a new standard of care, researcher says

MONDAY, Feb. 2 (HealthDay News) -- The sedative dexmedetomidine (Precedex) reduces the time patients stay on ventilators and results in less delirium than other more commonly used drugs for patients in intensive care units, a new study finds.

For patients in ICUs, delirium is a common side effect of being sedated for an extended period; it can affect as many as 85 percent of ICU patients. Some of these patients can have lingering mental problems when they leave the hospital, problems that may last for as long as six months, experts say.

"While dexmedetomidine provided a similar amount of time at the target level of sedation as midazolam [Versed], there were significant outcome improvements in other aspects of care," said lead researcher Dr. Richard R. Riker, director of critical care research at Maine Medical Center, in Portland.

"They came off the ventilator nearly two days faster, they had a much lower incidence of delirium, and they had a lower incidence of infection," he added.

The report was expected to be published in the Feb. 4 issue of the Journal of the American Medical Association. It is being released early to coincide with a presentation of the finding at the Society of Critical Care Medicine annual meeting, in Nashville, Tenn.

For the study, Riker's team randomly assigned 375 patients being treated in the ICU to dexmedetomidine or the more commonly used sedative midazolam. The trial ran from March 2005 to August 2007, and included patients from 68 medical centers in five countries.

Among patients receiving dexmedetomidine, 54 percent experienced delirium, compared with 76.6 percent of those receiving midazolam. In addition, patients receiving dexmedetomidine had more delirium-free days than patients receiving midazolam (2.5 days vs. 1.7 days), the researchers found.

Moreover, patients receiving dexmedetomidine spent less time on ventilators than patients receiving midazolam. Patients receiving midazolam remained on ventilators almost two days longer than those receiving dexmedetomidine (5.6 days vs. 3.7 days), Riker's group reports.

Patients receiving dexmedetomidine were more likely to experience a slow heartbeat, but were less likely to experience a rapid heartbeat or high blood pressure than those receiving midazolam, the researchers noted.

The reasons for these results are varied and not well-understood, Riker said. The drugs target different parts of the brain, which may account for some of the differences, he added.

Riker thinks this study provides evidence that will get more physicians to use dexmedetomidine. "As we get more studies, I think it may potentially become a new standard of care," he noted.

However, Dr. John P. Kress, an assistant professor of medicine at the University of Chicago and co-author of an accompanying journal editorial, thinks dexmedetomidine may be appropriate for some patients, but it won't replace other drugs.

"Dexmedetomidine is one of many drugs that are out there as options," Kress said. "Do I think it should be used for everybody? No. Do I think it has the potential for more than a rare occasional patient? I think this study shows that that's the case. Will it replace the other drugs? I don't think it will."

Kress would also like to see a study of dexmedetomidine that could determine whether the drug improves long-term outcomes.

More information

For more information on critical care, visit the U.S. National Library of Medicine.



SOURCES: Richard R. Riker, M.D., clinical assistant professor, medicine, University of Vermont College of Medicine, and director, critical care research, Maine Medical Center, Portland; John P. Kress, M.D., assistant professor, medicine, University of Chicago; Feb. 4, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Zoloft, Lexapro the Best of Newer Antidepressants
2. Newer Contraceptives Dont Increase Heart Risk
3. Newer Antipsychotics Pose Cardiac Risk: Study
4. Most Newer Antipsychotics No Better Than Older Ones, Just Different
5. Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
6. First generation antipsychotic drugs as effective as newer ones in some children
7. Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
8. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
9. Newer Prostate Cancer Treatment Similar to Traditional Surgery
10. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
11. Newer Sedative Might Help Patients on Ventilators
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Sedative May Reduce Delirium in ICU Patients
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: